| NCT00244309 | Case Comprehensive Cancer Center|GlaxoSmithKline | Prostate Cancer | 2005-11 | PHASE3 |
| NCT00824200 | Atlanta VA Medical Center|Emory University|University of Alabama at Birmingham | Nocturia | 2008-07 | PHASE4 |
| NCT02827578 | IlDong Pharmaceutical Co Ltd | Benign Prostate Hyperplasia | 2016-01 | PHASE3 |
| NCT06966804 | Penang Hospital, Malaysia | Stent Related Symptoms | 2025-06-01 | PHASE3 |
| NCT01100021 | VIVUS LLC | Erectile Dysfunction | 2010-02 | PHASE1 |
| NCT05834270 | Menoufia University | Prostatic Neoplasms|Prostate Disease|Prostate Obstruction|Prostate Hypertrophy | 2022-05-01 | NA |
| NCT07169773 | khaled Abdelsattar Gad Ibrahim | Prostate Hyperplasia | 2022-05-01 | NA |
| NCT00861757 | Eli Lilly and Company | Benign Prostatic Hyperplasia | 2009-03 | PHASE3 |
| NCT07091669 | Berlin-Chemie AG Menarini Group | Healthy Volunteers|Male | 2025-06-16 | PHASE1 |
| NCT02715024 | Astellas Pharma Taiwan, Inc. | Lower Urinary Tract Symptoms|Overactive Bladder|Benign Prostatic Hyperplasia (BPH) | 2007-09 | PHASE4 |
| NCT02038868 | Astellas Pharma Inc | Benign Prostate Hyperplasia | 2013-07-22 | PHASE2 |
| NCT04325880 | Mansoura University | Ureteral Stent|Stent Related Symptoms | 2021-12-01 | PHASE3 |
| NCT02138773 | Astellas Pharma China, Inc. | Healthy|Pharmacokinetics of Tamsulosin Hydrochloride | 2014-04 | PHASE1 |
| NCT04434378 | Jewish Hospital, Cincinnati, Ohio | Post Operative Urinary Retention | 2017-11-16 | PHASE4 |
| NCT01880619 | Mansoura University | Relieve of Ureteral Stent Symptoms | 2013-01 | PHASE4 |
| NCT02369744 | Albert Einstein Healthcare Network | Ureteral Calculus|Ureterolithiasis|Ureteral Stone | 2013-03 | PHASE4 |
| NCT02483793 | Phoenix Children´s Hospital | Disorder of Urinary Stent | 2015-07 | NA |
| NCT05197088 | Sengkang General Hospital | Renal Stone|Retrograde Intrarenal Surgery|Urolithiasis | 2022-01-09 | PHASE3 |
| NCT03887858 | Chong Kun Dang Pharmaceutical | Benign Prostatic Hyperplasia | 2019-03-11 | PHASE1 |
| NCT02757768 | Astellas Pharma Global Development, Inc. | Benign Prostatic Hyperplasia|Overactive Bladder | 2016-06-13 | PHASE4 |
| NCT02244320 | Boehringer Ingelheim | Prostatic Hyperplasia | 2002-09 | |
| NCT01736033 | Seoul National University Hospital|Astellas Pharma Korea, Inc.|Medical Research Collaborating Center, Seoul, Korea | Benign Prostate Hyperplasia | 2012-02 | PHASE4 |
| NCT00954889 | Samsung Medical Center | Benign Prostatic Hyperplasia | 2009-08 | NA |
| NCT00701779 | Siami, Paul F., M.D.|GlaxoSmithKline | Benign Prostatic Hyperplasia | 2005-09 | PHASE4 |
| NCT06181175 | Azienda Ospedaliero Universitaria Maggiore della Carita | Benign Prostatic Hyperplasia|Urinary Obstruction|Lower Urinary Tract Symptoms | 2021-10-01 | NA |
| NCT01404637 | Samsung Medical Center | Benign Prostatic Hyperplasia | 2011-07 | NA |
| NCT02862483 | IlDong Pharmaceutical Co Ltd | Benign Prostatic Hyperplasia|Erectile Dysfunction | 2016-03 | PHASE3 |
| NCT00382265 | Andrew Meltzer|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Ureterolithiases | 2008-01 | PHASE4 |
| NCT02266537 | Boehringer Ingelheim | Healthy | 2005-11 | PHASE1 |
| NCT02919436 | Anand Rughani, MD|MaineHealth | Post-operative Urinary Retention | 2016-03 | PHASE4 |
| NCT05032287 | Mansoura University | Urologic Diseases|Urolithiasis|Stone, Kidney | 2019-09-01 | NA |
| NCT05759767 | Mansoura University | Tamsulosin|Extracorporeal Shock Wave Lithotripsy|Stone, Kidney|Stone, Urinary|Pediatric Disorder | 2021-02-01 | NA |
| NCT01149746 | Teva Pharmaceuticals USA | Healthy | 2004-12 | PHASE1 |
| NCT04994431 | University of Massachusetts, Worcester|UMass Memorial Health | Thoracic Diseases|Urinary Retention | 2021-08-01 | PHASE4 |
| NCT02245529 | Boehringer Ingelheim | Prostatic Hyperplasia | 2005-03 | |
| NCT02279615 | St. Joseph´s Healthcare Hamilton | Overactive Bladder|Benign Prostatic Hyperplasia | 2021-12 | PHASE4 |
| NCT03384524 | Andrew Moshfeghi, MD, MBA|Case Western Reserve University | Diabetic Macular Edema | 2018-03 | PHASE1|PHASE2 |
| NCT06803030 | Bir Hospital|Nepal Health Research Council | Ureteral Stent-Related Symptom | 2025-08-30 | PHASE3 |
| NCT06737016 | Mansoura University | Posterior Urethral Valve | 2024-11-01 | PHASE3 |
| NCT01203371 | Apsen Farmaceutica S.A. | Hyperplasia | 2011-01-01 | PHASE3 |
| NCT02264184 | Boehringer Ingelheim | Healthy | 2008-09 | PHASE1 |
| NCT02245555 | Boehringer Ingelheim | Prostatic Hyperplasia | 2006-04 | |
| NCT01149733 | Teva Pharmaceuticals USA | Healthy | 2004-11 | PHASE1 |
| NCT04552431 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Chronic Prostatitis With Chronic Pelvic Pain Syndrome | 1997-09-30 | PHASE2 |
| NCT02486653 | University of Wisconsin, Madison | Urinary Retention|Urinary Tract Infections | 2015-08 | PHASE3 |
| NCT04557202 | Ain Shams University | Non-stented Ureteroscopic Laser Lithotripsy for Ureteric Stones | 2017-09-01 | PHASE3 |
| NCT00151567 | Rennes University Hospital|Ministry of Health, France|Yamanouchi | Ureterolithiasis|Ureteral Calculi | 2002-02 | PHASE3 |
| NCT01953887 | Astellas Pharma Europe B.V. | EC905|Pharmacokinetics|Healthy Subjects | 2010-03 | PHASE1 |
| NCT05150899 | Assiut University | Renal Colic|Ureter Stone | 2021-11-30 | |
| NCT01777269 | GlaxoSmithKline | Prostatic Hyperplasia | 2013-02-18 | PHASE4 |
| NCT04159077 | McMaster University | Urinary Catheterization|Thoracic Surgery|Thoracic Epidural Analgesia | 2021-07-30 | PHASE3 |
| NCT06677177 | ALI KAMAL M. SAMI|University of Sulaimani | Lower Urinary Tract Symptoms | 2016-02-16 | NA |
| NCT06262048 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph´s | Urinary Retention Postoperative | 2024-10-01 | PHASE2 |
| NCT06754410 | South Valley University | Lower Ureteric Stones | 2021-03-01 | PHASE3 |
| NCT01560091 | Albert Einstein Healthcare Network | Kidney Stones | 2012-03 | PHASE3 |
| NCT01471678 | GlaxoSmithKline | Prostatic Hyperplasia | 2011-06-30 | PHASE1 |
| NCT06867315 | First Affiliated Hospital of Zhejiang University|Shanghai Jiao Tong University Affiliated Sixth People´s Hospital|The First Affiliated Hospital of University of Science and Technology of China|First People´s Hospital of Hangzhou|Fujian Provincial Hospital | Benign Prostatic Hyperplasia | 2024-05-29 | NA |
| NCT00333112 | Astellas Pharma Inc | Urinary Incontinence | 2006-05 | PHASE4 |
| NCT05890235 | Xintian Pharmaceutical | Chronic Prostatitis | 2018-11-16 | PHASE4 |
| NCT02958878 | Ascension Health | Postoperative Urinary Retention | 2017-01-03 | PHASE4 |
| NCT07322991 | Il-Yang Pharm. Co., Ltd. | Healthy Adult Male | 2025-10-14 | PHASE1 |
| NCT03609580 | Hackensack Meridian Health | Urinary Retention | 2018-05-07 | PHASE1|PHASE2 |
| NCT07562282 | Ain Shams University | Kidney Stone|Ureteric Stone | 2025-12-01 | NA |
| NCT03314025 | CHU de Quebec-Universite Laval | Urinary Retention | 2017-10-06 | PHASE2 |
| NCT07114848 | Liaquat National Hospital & Medical College | Ureteral Stent-Related Symptom|Alpha Blocker|Anticholinergics|Ureter Calculi | 2024-06-13 | PHASE4 |
| NCT06020963 | Taichung Armed Forces General Hospital | Detrusor Underactivity | 2023-08-11 | NA |
| NCT00379067 | Astellas Pharma Inc|Astellas Pharma Europe Ltd.|Boehringer Ingelheim | Benign Prostatic Hyperplasia | 2005-10 | PHASE4 |
| NCT03976934 | Georgios Koukoulis|University of Thessaly | Inguinal Hernia|Urinary Retention | 2020-02-01 | PHASE1|PHASE2 |
| NCT01495026 | GlaxoSmithKline | Prostatic Hyperplasia | 2011-11-06 | PHASE1 |
| NCT02169713 | Astellas Pharma Europe B.V. | Healthy Subjects|Pharmacokinetics|Drug-Drug Interaction (DDI) | 2014-05 | PHASE1 |
| NCT01175382 | University of Alabama at Birmingham | Overactive Bladder|Lower Urinary Tract Symptoms | 2010-07 | PHASE2|PHASE3 |
| NCT02244242 | Boehringer Ingelheim | Prostatic Hyperplasia | 1998-07 | PHASE4 |
| NCT05725122 | Services Hospital, Lahore | Renal Stone | 2018-02-01 | NA |
| NCT05537272 | University Hospital of Split | Lower Urinary Tract Symptoms|Voiding Disorders|Pain|Quality of Life | 2022-09-01 | PHASE4 |
| NCT05818670 | Mansoura University | BPH | 2020-11-11 | PHASE4 |
| NCT01534351 | Merck Sharp & Dohme LLC | Benign Prostatic Hyperplasia | 2013-08-01 | PHASE3 |
| NCT01726270 | Boehringer Ingelheim | Lower Urinary Tract Symptoms | 2012-11 | PHASE2 |
| NCT02245490 | Boehringer Ingelheim | Prostatic Hyperplasia | 2003-01 | PHASE4 |
| NCT05657990 | Hackensack Meridian Health | Urinary Retention | 2023-04-03 | EARLY_PHASE1 |
| NCT02244229 | Boehringer Ingelheim | Prostatic Hyperplasia | 1998-04 | PHASE4 |
| NCT03614052 | Pontificia Universidad Catolica de Chile | Ureterolithiasis|Ureteral Calculi|Urolithiasis | 2018-06-01 | PHASE4 |
| NCT02180997 | Jeil Pharmaceutical Co., Ltd. | LUTS|Benign Prostatic Hyperplasia|Overactive Bladder | 2014-07 | PHASE1 |
| NCT05439902 | Centre Hospitalier Universitaire de N?mes | Multiple Sclerosis|Dysuria|Lower Urinary Tract Symptoms|Voiding Dysfunction|Urinary Retention | 2022-10-05 | NA |
| NCT01209988 | Asan Medical Center|Astellas Pharma Inc | Prostatic Neoplasms, Prostatectomy | 2010-04 | NA |
| NCT05494567 | Mansoura University | Benign Prostatic Hyperplasia|Overactive Bladder | 2021-11-08 | PHASE4 |
| NCT04682366 | Wake Forest University Health Sciences | Urinary Retention | 2021-10-19 | PHASE4 |
| NCT02443844 | Diskapi Teaching and Research Hospital | Bladder Cancer | 2015-02 | PHASE4 |
| NCT01018511 | Astellas Pharma Europe B.V. | Benign Prostatic Hyperplasia|Lower Urinary Tract Symptoms | 2010-01-11 | PHASE3 |
| NCT05401032 | Clinical Academic Center (2CA-Braga) | BPH|LUTS(Lower Urinary Tract Symptoms) | 2024-12-20 | PHASE2 |
| NCT00359905 | RECORDATI GROUP | Benign Prostatic Hyperplasia | 2006-05 | PHASE3 |
| NCT00457457 | Pfizer | Prostatic Hyperplasia | 2007-05 | PHASE2 |
| NCT01489696 | Astellas Pharma Inc | Cardiovascular|Healthy Subjects|Pharmacokinetics | 2010-08 | PHASE1 |
| NCT02417831 | Boehringer Ingelheim | Prostatic Hyperplasia | 2015-04-30 | PHASE1 |
| NCT01657851 | GlaxoSmithKline | Prostatic Hyperplasia | 2012-08-23 | PHASE1 |
| NCT01568918 | Mayo Clinic | Postoperative Urinary Retention | 2012-05 | PHASE3 |
| NCT00600405 | MaineHealth|Maine Medical Center Mentored Research Committee | Nephrolithiasis|Ureteral Calculi | 2006-08 | NA |
| NCT06707181 | Beni-Suef University | Lower Ureteral Stones | 2023-11-01 | PHASE3 |
| NCT00831701 | University of Zurich | Ureteral Calculi | 2006-09 | NA |
| NCT03887871 | Chong Kun Dang Pharmaceutical | Benign Prostatic Hyperplasia | 2019-03-11 | PHASE1 |
| NCT02417844 | Boehringer Ingelheim | Prostatic Hyperplasia | 2015-04 | PHASE1 |
| NCT00489723 | HaEmek Medical Center, Israel | Kidney Stones | 2007-05 | |
| NCT01957189 | GlaxoSmithKline | Prostatic Hyperplasia | 2013-10-25 | PHASE1 |
| NCT03856242 | I.M. Sechenov First Moscow State Medical University | Ischaemic Heart Disease (IHD)|Benign Prostatic Hyperplasia (BPH)|Lower Urinary Tract Symptoms (LUTS) | 2015-09-01 | PHASE4 |
| NCT02972268 | Jeil Pharmaceutical Co., Ltd. | Lower Urinary Tract Symptoms|Benign Prostatic Hyperplasia | 2016-02-01 | PHASE3 |
| NCT03799120 | Gundersen Lutheran Medical Foundation | Ureteral Diseases | 2019-02-18 | PHASE4 |
| NCT05753670 | Endeavor Health | Postoperative Retention of Urine | 2023-07-01 | PHASE3 |
| NCT05790902 | Armed Forces Institute of Urology, Rawalpindi | Silodosin, Tamsulosin, Medical Expulsive Therapy, Distal Ureteric Calculi | 2022-09-01 | PHASE1 |
| NCT03750656 | University of Kansas Medical Center | Lower Urinary Tract Symptoms | 2018-11-12 | PHASE4 |
| NCT06558032 | Dexa Medica Group | Healthy | 2023-11-06 | PHASE1 |
| NCT01167062 | Chiang Mai University | Ureteral Calculi | 2010-06 | PHASE4 |
| NCT05977647 | Getz Pharma | Ureteric Stone of Lower Third of Ureter | 2024-09-01 | PHASE4 |
| NCT05570084 | Princess Margaret Hospital, Hong Kong | Stone, Urinary | 2022-05-31 | PHASE3 |
| NCT00451061 | Soroka University Medical Center | Renal Colic | 2007-04 | PHASE4 |
| NCT00970632 | Eli Lilly and Company | Benign Prostatic Hyperplasia (BPH) | 2009-10 | PHASE3 |
| NCT02509104 | GlaxoSmithKline | Prostatic Hyperplasia | 2015-07-30 | PHASE1 |
| NCT00090103 | GlaxoSmithKline | Prostatic Hyperplasia | 2003-11 | PHASE3 |
| NCT02058368 | GlaxoSmithKline | Prostatic Hyperplasia | 2014-02-10 | PHASE3 |
| NCT01215708 | University of Sao Paulo General Hospital|Coordena??o de Aperfei?oamento de Pessoal de Nível Superior. | Renal Calculi | 2006-08 | PHASE3 |
| NCT07274228 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph´s | Chronic Kidney Disease (CKD) | 2008-01-01 | |
| NCT06257576 | Emory University|ABRAHAM J & PHYLLIS KATZ FOUNDATION | Postoperative Urinary Tract Infection | 2024-02-26 | PHASE3 |
| NCT07357324 | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Benign Prostatic Hyperplasia|Nocturia Associated With Nocturnal Polyuria | 2024-12-01 | PHASE4 |
| NCT03314259 | National University Hospital, Singapore|National University of Singapore | Urinary Retention|Inguinal Hernia | 2017-12-01 | EARLY_PHASE1 |
| NCT02058576 | GlaxoSmithKline | Urologic Diseases | 2014-02-11 | PHASE1 |
| NCT03808155 | Kantonsspital Graubünden | Urinary Retention Postoperative|Arthropathy of Knee|Arthropathy of Hip | 2019-08-01 | PHASE4 |
| NCT02684344 | University of Rochester | Post-Operative Urinary Retention | 2016-02 | NA |
| NCT07467343 | Ain Shams University | Benign Prostatic Hyperplasia|Lower Urinary Tract Symptoms | 2026-03-22 | PHASE4 |
| NCT03879746 | Assiut University | Premature Ejaculation | 2019-04 | PHASE3 |
| NCT02264171 | Boehringer Ingelheim | Healthy | 2008-04 | PHASE1 |
| NCT00913315 | Chongqing Medical University|Fuling Central Hospital of Chongqing City | Prostatitis | 2009-08 | NA |
| NCT02634489 | Astellas Pharma Europe B.V. | Phase 1|Healthy|Benign Prostatic Hyperplasia|Lower Urinary Tract Symptoms | 2009-03 | PHASE1 |
| NCT03246880 | Chong Kun Dang Pharmaceutical | Benign Prostatic Hyperplasia | 2015-09 | PHASE3 |
| NCT00448123 | Robert Swor|Corewell Health East | Kidney Stones|Ureteral Stones | 2007-02 | NA |
| NCT04641507 | Beni-Suef University | Lower Ureteric Stones | 2020-01-01 | PHASE4 |
| NCT04859660 | University of Arizona | Urinary Retention Postoperative | 2021-04-16 | PHASE2 |
| NCT06809205 | Fayoum University Hospital | BPH With Other Lower Urinary Tract Symptoms | 2023-04-20 | PHASE4 |
| NCT02573311 | Boehringer Ingelheim | Urological Manifestations | 2015-09-23 | PHASE3 |
| NCT01937871 | Eli Lilly and Company | Benign Prostate Hyperplasia|Erectile Dysfunction | 2013-09 | PHASE3 |
| NCT01028014 | University of Alabama at Birmingham|Astellas Pharma Inc | Urethral Sphincter Activity | 2010-04 | NA |
| NCT00340704 | Boehringer Ingelheim | Bladder, Neurogenic | 2006-04 | PHASE2 |
| NCT07146711 | Berlin-Chemie AG Menarini Group | Healthy Adult Males Volunteers | 2025-03-03 | PHASE1 |
| NCT01829893 | Korea University Anam Hospital|GL Pharm Tech Corporation | Benign Prostatic Hyperplasia (BPH) | 2012-01 | PHASE1 |
| NCT01589263 | VA Office of Research and Development | Benign Prostatic Hyperplasia|Lower Urinary Track Symptoms | 2012-06-01 | PHASE2 |
| NCT00478998 | Hadassah Medical Organization | Upper Tract Ureterolithiasis | | PHASE2 |
| NCT03709992 | Mansoura University|Amiri Hospital | Ureter Stone|Quality of Life|Ureter Obstruction | 2020-12-18 | NA |
| NCT05531344 | REMD Medical Technology|RenJi Hospital|Dongfang Hospital Affiliated to Tongji University|Shanghai Pudong Hospital|Qilu Hospital of Shandong University|Ningbo No.2 Hospital|Shangdong Yiyuan Hospital|Tongji Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Hunan Provincial People´s Hospital | Benign Prostatic Hyperplasia | 2020-08-20 | PHASE2|PHASE3 |
| NCT02303769 | GL Pharm Tech Corporation | Benign Prostatic Hyperplasia | 2014-03 | PHASE3 |
| NCT00606983 | Seoul National University Hospital | Rectal Cancer|Urinary Retention | 2007-05 | PHASE3 |
| NCT00796614 | Boehringer Ingelheim | Bladder, Neurogenic | 2008-01 | PHASE2|PHASE3 |
| NCT00507455 | Astellas Pharma Inc | Lower Urinary Tract Symptoms|Bladder Outlet Obstruction | 2007-06 | PHASE2 |
| NCT04359979 | Sheba Medical Center | Thyroid Eye Disease|Eyelid Diseases | 2020-05-01 | NA |
| NCT07310797 | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | Ureteral Calculi | 2026-01-01 | PHASE4 |
| NCT01254071 | GlaxoSmithKline | Prostatic Hyperplasia | 2010-09-10 | PHASE1 |
| NCT04987892 | NeoTract, Inc. | BPH | 2021-12-06 | PHASE4 |
| NCT06568718 | NPO Petrovax | Lower Urinary Tract Symptoms|Prostatic Hyperplasia | 2023-03-20 | NA |
| NCT02180789 | Astellas Pharma Inc|Astellas Pharma Taiwan, Inc. | Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) | 2013-03 | PHASE4 |
| NCT06843538 | TriHealth Inc. | Postoperative Urinary Retention (POUR) | 2025-02-03 | PHASE3 |
| NCT01741454 | University of Wisconsin, Madison | Ureteral Obstruction | 2012-11 | PHASE4 |
| NCT02003742 | RECORDATI GROUP | Lower Urinary Tract Symptoms | 2013-09 | PHASE3 |
| NCT02518971 | University of Michigan | Postoperative Urinary Retention | 2015-08 | PHASE3 |
| NCT04232683 | The Cleveland Clinic | Urinary Retention | 2019-12-18 | EARLY_PHASE1 |
| NCT04807569 | Joint-Stock Company North-West Center for Evidence-Based Medicine, Russian Federation | Bladder Hypersensitivity | 2021-04-01 | NA |
| NCT00147654 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc. | Urinary Incontinence | 2004-11 | PHASE4 |
| NCT02095665 | Nova Scotia Health Authority | Nephrolithiasis | 2014-01-01 | PHASE4 |
| NCT07308002 | Mansoura University | Lower Urinary Tract Symptoms|Prostate Obstruction | 2026-01-01 | PHASE4 |
| NCT02239484 | Hanmi Pharmaceutical Company Limited | Erectile Dysfunction|Benign Prostatic Hyperplasia | 2014-03 | PHASE1 |
| NCT01457573 | Timothy Boone, MD, PhD|Astellas Pharma US, Inc. | Lower Urinary Tract Symptoms | 2011-10 | PHASE4 |
| NCT06955533 | Ain Shams University | Stent Related Symptoms | 2024-04-01 | NA |
| NCT01294592 | GlaxoSmithKline | Prostatic Hyperplasia | 2010-12-22 | PHASE4 |
| NCT01747993 | Assistance Publique - H?pitaux de Paris | Urinary Retention | 2013-01 | PHASE3 |
| NCT01021332 | Astellas Pharma Europe B.V. | Lower Urinary Tract Symptoms|Benign Prostatic Hyperplasia | 2010-04-26 | PHASE3 |
| NCT03144596 | Kocatepe University | Benign Prostatic Hyperplasia|Pupil Anomaly|Choroid Disease | 2015-10-29 | PHASE4 |
| NCT00771394 | Astellas Pharma Inc | Benign Prostatic Hyperplasia|Benign Prostatic Hypertrophy|Overactive Bladder | 2008-10 | PHASE4 |
| NCT05551221 | Xintian Pharmaceutical | Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms | 2022-07-18 | PHASE4 |
| NCT06753526 | Sohag University | Stone Lower Ureter | 2023-07-01 | PHASE4 |
| NCT04107896 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Benign Prostatic Hyperplasia | 2017-08-31 | PHASE4 |
| NCT02245503 | Boehringer Ingelheim | Prostatic Hyperplasia | 2003-05 | |
| NCT07156916 | Berlin-Chemie AG Menarini Group | Healthy Volunteer Male Subjects | 2025-09-08 | PHASE1 |
| NCT05415748 | University of California, San Francisco|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Benign Prostatic Hyperplasia|Lower Urinary Tract Symptoms | 2021-09-18 | PHASE4 |
| NCT02266524 | Boehringer Ingelheim | Urination Disorders | 2005-01 | PHASE1 |
| NCT02052713 | GlaxoSmithKline | Urologic Diseases | 2014-02-19 | PHASE1 |
| NCT00540124 | Eli Lilly and Company | Benign Prostatic Hyperplasia | 2007-10 | PHASE2 |
| NCT03524339 | University Hospitals Cleveland Medical Center | Urinary Retention|Lower Urinary Tract Symptoms|Stress Urinary Incontinence|Pelvic Organ Prolapse | 2018-08-01 | PHASE2|PHASE3 |
| NCT02244281 | Boehringer Ingelheim | Lower Urinary Tract Symptoms | 2001-05 | PHASE2 |
| NCT02033798 | The Catholic University of Korea | Chronic Kidney Failure|Prostatic Hyperplasia | 2014-02 | NA |
| NCT04819828 | Hospital Regional de Alta Especialidad del Bajio | Renal Stone | 2010-01-01 | PHASE4 |
| NCT02034604 | Samsung Medical Center | Neurogenic Lower Urinary Tract Dysfunction | 2013-12 | PHASE4 |
| NCT00510406 | Astellas Pharma Inc | Lower Urinary Tract Symptoms|Prostatic Hyperplasia | 2007-01 | PHASE2 |
| NCT04147806 | Albert Einstein College of Medicine | Prostate Cancer | 2016-08-01 | PHASE1 |
| NCT03027115 | Memorial Health University Medical Center | Hernia|Urinary Retention | 2017-01-13 | PHASE4 |
| NCT04491526 | Antonio Nocito, MD | Urinary Retention|Inguinal Hernia | 2020-11-01 | PHASE4 |
| NCT01533597 | Soonchunhyang University Hospital | Overactive Bladder | 2010-12 | PHASE4 |
| NCT00223717 | Vanderbilt University | Hypertension | 2001-01 | PHASE1 |
| NCT04597372 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)|Johns Hopkins University | Urinary Retention Postoperative | 2021-11-03 | PHASE2 |
| NCT02656173 | Astellas Pharma Inc|Astellas Pharma Singapore Pte. Ltd. | Overactive Bladder | 2016-01-25 | PHASE4 |
| NCT05941806 | CHU de Quebec-Universite Laval|Fédération des médecins résidents du Québec | Urinary Retention|Colorectal Surgery|Rectal Resection|Post-operative Urinary Retention|Tamsulosin | 2023-08-01 | PHASE3 |